Advanced diagnostics such as comprehensive genomic profiling using liquid biopsy can accelerate drug development and help treatment selection for patients,” said Guardant Health AMEA CEO, Mr Simranjit Singh, in his keynote address at the BIO Asia-Taiwan Conference and Exhibition in Taipei this morning.